In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...
Cure Today2 天
Identifying Drivers of Exceptional Response to Immunotherapy in Metastatic RCC
In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...
Cure Today4 天
Study Shows Poor Outcomes in BRAF V600E-Mutant Metastatic CRC
BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical outcomes in patients receiving ...